首页> 外文期刊>The Internet Journal of Tropical Medicine >The efficacy of artesunate in the treatment of urinary schistosomiasis in ogoja,Cross river state, nigeria
【24h】

The efficacy of artesunate in the treatment of urinary schistosomiasis in ogoja,Cross river state, nigeria

机译:青蒿琥酯治疗尼日利亚跨河州奥古贾市的尿血吸虫病的疗效

获取原文
       

摘要

The efficacy of artesunate in the treatment of urinary schistosomiasis was investigated among 250 randomly selected subject aged 6 – 50 years in Ogoja, Nigeria. In the parasitological examination, infection was confirmed in 25 (10%) of the 250 subjects screened. Artesunate were administered orally at 4mg/kg body weight. Adverse effects due to drug reactions were assessed 3 days after medication and all perceived symptoms of illness were treated. The cure rate was evaluated after 2 weeks of treatment. There cure rate was 16 (64.0%) after treatment. There was a significant reduction in prevalence from a pre-treatment value of 10% to a post-treatment value of 3.6%. The intensity of infection also reduced significantly (p<.001) from 17.2% -3.1% for pre-treatment and post-treatment respectively giving a reduction rate of 82.1%. This study has shown that artesunate is effective in the treatment of schistosomiasis. It is recommended that a combination of artesunate and praziquantel, might produce a more effective treatment than the separate use of either drug. Introduction Human schistomiasis remains one of the most important parasitic diseases in the tropics for which there are no vaccines1. Chemotherapy with praziquantel currently offers the most feasible means of controlling human schistosomiasis, at least in the short term2,3. There are concerns however that schistosoma haematobium the aetiologic agent of urinary schistosomiasis is developing resistance to praziquantel or at least have the tendency to do so4,5. Studies conducted elsewhere have associated praziquental with low cure and egg production rates after the administration of a single dose of the drug6,7,8. Subsequently, communities in a very intense focus of S. mansoni infection in Senegal showed unexpectedly low rate following treatment with praziquantel9,10. Perhaps the best evidence so far of resistance to praziquantel is the failure of Ismail et al.11 to cure some natural S. mansoni infection in some Egyptian patients with three doses of the drug.The potential problem of praziquantel resistance led to a search for alternative drug for the treatment and control of schistosomiasis12,13. Although artemisinin and it derivatives such as artesunate, arteether, artemether and dihydroartemisinin were originally developed for the treatment of malaria, they have antischistosomal activity13,14. In vitro treatment of adult schistosomes with artemether, for example led to a significant reduction in the glycogen content of the worms and extensive tegumental damage15.For more than a decade, evidence has been accumulating of the effect of treating S. japoniucum and S. mansoni infections with one of the artemisinins16. Artemether appears to exhibit maximum activity against the liver stages and adult worms being less susceptible15. In human trials, administration of artemisinin derivatives (artesunate, artemeter) at a dose of 6mg/kg every 15 days during the S. japonicum transmission season resulted in the effective control of schistosomiasis in highly endemic areas in China17. Recently, treatment of schistosomiasis with the combination of artesunate and praziquantel show that more than 80% curative18,19. Artesunate not only exhibits antimalaria properties, but also possesses strong activities against schistosomes. The objective of our present research is to determine the efficacy of artesunate in the treatment of urinary schistosomiasis in patients attending the General Hospital, Ogoja in the Cross River State of Nigeria. Materials And Methods Sample CollectionThe General Hospital, Ogoja in Cross River State of Nigeria was chosen for this study because a cross section of members of this community often visit the Hospital to sort out their health needs. Ogoja is in Cross River State, Nigeria, which lies between latitude 5°32' and 4°27' North and longitude 7°50' and 2°20' East. There are two different climatic seasons in the area, the rainy season from March to October and the dry season
机译:在尼日利亚Ogoja的250名年龄在6至50岁的随机选择的受试者中,调查了青蒿琥酯在治疗尿道血吸虫病中的功效。在寄生虫学检查中,在筛选出的250名受试者中有25名(10%)确认感染。青蒿琥酯以4mg / kg体重口服。在用药3天后评估由于药物反应引起的不良反应,并治疗所有感觉到的疾病症状。治疗2周后评估治愈率。治疗后治愈率为16(64.0%)。患病率从治疗前的10%显着降低到治疗后的3.6%。治疗前和治疗后的感染强度也分别从17.2%-3.1%显着降低(p <.001),降低率为82.1%。这项研究表明青蒿琥酯对血吸虫病有效。建议将青蒿琥酯和吡喹酮组合使用比单独使用两种药物更有效。引言人类血吸虫病仍然是热带地区最重要的寄生虫病之一,目前尚无疫苗1。目前,至少在短期内,使用吡喹酮进行化学疗法可提供控制人类血吸虫病的最可行方法[2,3]。然而,有人担心,血吸虫病的血吸虫病血吸虫血吸虫病正在对吡喹酮产生抗药性,或至少有这样做的趋势[4,5]。在其他地方进行的研究普遍认为,单剂药物治疗后治愈率和产卵率较低[6,7,8]。随后,在使用吡喹酮9,10治疗后,塞内加尔非常关注曼氏沙门氏菌感染的社区感染率意外降低。迄今为止,对吡喹酮耐药的最好证据可能是Ismail等人(11)无法用三剂该药治愈某些埃及患者的自然曼氏沙门氏菌感染。吡喹酮耐药的潜在问题导致人们寻求替代方法用于治疗和控制血吸虫病的药物12,13。尽管青蒿素及其衍生物(例如青蒿琥酯,青蒿醚,青蒿素醚和二氢青蒿素)最初是用于治疗疟疾的,但它们具有抗血吸虫病的活性13,14。例如,用蒿甲醚对成人血吸虫进行体外治疗可导致蠕虫糖原含量显着降低和广泛的皮下损害15。十多年来,已有证据证明日本血吸虫和曼氏沙门氏菌的治疗效果不断累积。一种青蒿素的感染16。蒿甲醚似乎表现出针对肝脏阶段的最大活性,而成虫则不那么容易感染15。在人体试验中,在日本血吸虫传播季节期间,每15天以6mg / kg的剂量施用青蒿素衍生物(青蒿琥酯,artemeter)可有效控制中国高流行地区的血吸虫病17。最近,使用青蒿琥酯和吡喹酮联合治疗血吸虫病显示,有80%以上的治愈率18,19。青蒿琥酯不仅具有抗疟疾特性,而且还具有针对血吸虫的强大活性。我们当前研究的目的是确定青蒿琥酯在尼日利亚克罗斯河州奥戈贾综合医院就诊的患者中的血吸虫病治疗效果。材料和方法样本收集本研究选择了尼日利亚Cross River州Ogoja的总医院,因为该社区中有很多人经常去医院检查他们的健康需求。 Ogoja位于尼日利亚的Cross River State,位于北纬5°32'和4°27'之间,东经7°50'和2°20'之间。该地区有两个不同的气候季节,三月至十月的雨季和旱季

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号